Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds
April 17, 2024 08:00 ET
|
Longeveron
Longeveron raises gross proceeds of ~$6.2 M from exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares of its common stock.
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
April 15, 2024 08:30 ET
|
Longeveron
Data from Longeveron's CLEAR MIND Phase 2a clinical trial evaluating Lomecel-B in Alzheimer’s Disease has been accepted for two presentations at AAIC.
Longeveron Announces Closing of $5.2 Million Public Offering
April 11, 2024 17:17 ET
|
Longeveron
Longeveron announces closing of previously announced public offering, raising $5.25 million in gross proceeds.
Longeveron Announces Pricing of $5.25 Million Public Offering
April 08, 2024 14:15 ET
|
Longeveron
Longeveron prices $5.15 million public offering with certain board member and insider participation.
Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals
April 08, 2024 08:30 ET
|
Longeveron
CEO Letter to Shareholders. Update on overall strategy, business objectives, approach to capital allocation, and 2024 key priorities and goals.
Longeveron Announces 1-for-10 Reverse Stock Split
March 19, 2024 16:01 ET
|
Longeveron
MIAMI, March 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for unmet medical...
Longeveron Reports Year-End 2023 Results and Provides Corporate Update
February 27, 2024 16:05 ET
|
Longeveron
Company Announces 2024 Strategic Priorities Focused on Advancement of Lomecel-B™ in Hypoplastic Left Heart Syndrome ELPIS II Phase 2 Trial of Lomecel-B™ in HLHS Continues Enrollment; Completion of...
Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024
February 21, 2024 16:05 ET
|
Longeveron
MIAMI, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs,...
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™
January 29, 2024 08:00 ET
|
Longeveron
MIAMI, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and...
Longeveron Announces Closing of $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 22, 2023 16:05 ET
|
Longeveron
MIAMI, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and...